DXCM logo

DXCM
Dexcom Inc

10,005
Mkt Cap
$22.31B
Volume
11.13M
52W High
$89.98
52W Low
$54.11
PE Ratio
26.36
DXCM Fundamentals
Price
$61.63
Prev Close
$57.82
Open
$59.91
50D MA
$63.23
Beta
0.83
Avg. Volume
4.25M
EPS (Annual)
$2.09
P/B
8.04
Rev/Employee
$420,000.00
$26,304.04
Loading...
Loading...
News
all
press releases
Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
DexCom Sets 2030 Margin Targets, Projects Double-Digit Revenue Growth, Authorizes $1 Billion Share Buybackread more...
Benzinga·15h ago
News Placeholder
More News
News Placeholder
Dexcom Just Made A Lofty Promise To Its Investors Why Analysts Are Bullish
Dexcom Just Made A Lofty Promise To Its Investors Why Analysts Are Bullish...
Yahoo! Finance: News·16h ago
News Placeholder
Here's Why DexCom (DXCM) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·19h ago
News Placeholder
Futures Tumble As Reality Returns And Yields, Oil And Dollar Soar
false
Zero Hedge·20h ago
News Placeholder
Dexcom Announces Governance Enhancements Ahead of 2026 Investor Day
DexCom, Inc. (NASDAQ:DXCM) today announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic and financial vision to best position the company for future growth. We look forward to articulating our exciting vision for...
Business Wire·2d ago
News Placeholder
Here Are Tuesday's Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe's, Matador Resources, Toast and More
Here Are Tuesday's Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe's, Matador Resources, Toast and More...
Yahoo! Finance: News·4d ago
News Placeholder
10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up
TXG beats Q1 estimates as consumables growth, margin expansion and lower operating costs narrow losses year over year.
Zacks·8d ago
News Placeholder
PACB Q1 Earnings Beat, Revenues Miss Estimates, Gross Margin Down
PacBio beats Q1 earnings estimates as consumables growth and cost cuts offset flat revenue and a weaker gross margin.
Zacks·8d ago
News Placeholder
QDEL Stock Down as Q1 Earnings Miss Estimates, Revenues Down Y/Y
QuidelOrtho posts a wider Q1 loss as revenues fell 10.5% year over year, with weakness in respiratory testing pressuring margins and cash flow.
Zacks·10d ago
News Placeholder
Solventum Stock Down Despite Q1 Earnings & Revenues Beat Estimates
SOLV beats Q1 earnings and revenue estimates as growth in MedSurg, Dental and HIS offset sales decline and margin pressure.
Zacks·10d ago
<
1
2
...
>

Latest DXCM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.